FDA Approves First Gene Therapy for Bladder Cancer

PLUS: New Trial for Hereditary Angioedema

Hi friends 👋🏼,

Here are the top stories in the world of medical biology:

  • First Gene Therapy for Bladder Cancer Approved READER REQUEST

  • Phase I/II Clinical Trial Initiated for Hereditary Angioedema

  • CRISPR Shows Promise for Retinitis Pigmentosa READER REQUEST

  • TALENs as Targeted Therapy for HPV-Induced Cancer READER REQUEST

Cell & Gene Therapy Clinical Trial Database Coming Soon.

Join the Inner Circle for access.

(if you’re already a member, ignore this little box)


📣 First Gene Therapy for Bladder Cancer Approved

What is non-muscle invasive bladder cancer (NMIBC)? NMIBC is a form of bladder cancer that is present in the surface layers of the bladder - it has not invaded deeper into the bladder or other parts of the body. Currently, the first treatment option for NMIBC is to add Bacillus Calmette-Guerin (BCG), a bacteria, through a catheter. Yes, you read that right - BCG is a bacteria that does not cause serious disease and it is added into the bladder to help “turn on” the immune system in the bladder and kill the bladder cancer. 🤯 However, BCG therapy will fail in 40-50% of patients leaving them with only one other option: removal of the whole bladder.

1/ Adstiladrin® is the first gene therapy approved for BCG-unresponsive NMIBC.

2/ The FDA approval of Adstiladrin® was based on the results of a Phase 3 clinical trial where 51% of patients had a complete response to the gene therapy eliminating their bladder cancer and remaining free of cancer recurrence for at least 12 months.

How Adstiladrin® gene therapy works 👇🏼

Subscribe to The Cure to read the rest.

Become a paying subscriber of The Cure to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In

A subscription gets you:
Submit your disease request and we'll find and report on clinical trials, emerging medical technology, and innovative therapeutics.
Easy to understand science written for the everyday person.
Articles delivered to your inbox every Sunday.
Plus - No ads. Ever.